Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

By afschroeder • March 12, 2026

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine P, Yan M, Lee S, Kim NJ, Rodriguez R, Bishop P, Sanchez R, Orpilla J, Le Verche V, Xu S, Chen ISY, Kitchen S, Breton L, Bartlett JS, Do MH, Zhen A. Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model. Mol Ther. 2026 Mar 10:S1525-0016(26)00193-0. doi: 10.1016/j.ymthe.2026.03.008. Epub ahead of print. PMID: 41814653.

Tags: Hematology/Oncology, Post Doc, Publications

Related Posts

Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller[...]

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]